Left main (LM) percutaneous coronary intervention (PCI) using the latest-generation Resolute Onyx zotarolimus-eluting stent, which includes large and extra-large vessel platforms, is associated with a low target lesion failure (TLF) rate, according to 1-year data from the largest prospective registry of this drug-eluting stent (DES).